Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Liontrust reports stable AuMA in first quarter

(Sharecast News) - Shares in Liontrust jumped on Thursday morning after the company reported stable assets under management in the first quarter and increased investor demand for actively managed funds. Assets under management and advice totalled £22.6bn by 30 June, unchanged from the end of the previous financial year on 31 March.

That was despite net ouflows increasing to £1.1bn, up from £0.9bn in the same period the year before.

"Liontrust has spoken for the last nine months about how investors will need to search wider for alpha going forward and why this means a more positive environment for active management," said chief executive John Ions.

"We have now begun to see investors, led by institutional clients, turn more towards actively managed funds and diversify geographically, with Europe and the UK outperforming the US stock market over the first half of 2025."

Ions said that the company was continuing to make progress against its strategic objectives, including broadening distribution institutionally and internationally and expanding the fund range.

Shares were 5.8% higher at 383.5p by 0833 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.